Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: UMLS:C0007097 (carcinoma)
152,788 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor content of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma have been examined in female Sprague-Dawley rats. The rats were fed either a high-fat (20% corn oil) or low-fat (0.5% corn oil) diet with or without 0.005% indomethacin starting 7 days after intragastric administration of a single dose of 5 mg 7,12-dimethylbenz(a)anthracene. The results demonstrated that indomethacin completely blocked the stimulatory effect of fat on tumorigenesis, as demonstrated by a decreased tumor incidence, a decreased number of tumors per group, and an increased latency. Contrary to what had been expected, however, indomethacin promoted tumor proliferation in both the high- and low-fat diet groups, as evidenced by an increased tumor size, an increased bromodeoxyuridine-labeling index, and a decreased potential tumor-doubling time. No significant difference in either the estrogen receptor or progesterone receptor content of the tumor was noted. It can be concluded, therefore, that indomethacin significantly reduced tumorigenesis in the high-fat diet group but significantly promoted tumor proliferation in both the high- and low-fat diet groups.
...
PMID:Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. 190 95

The mammary carcinoma cell line MFM-223 is characterized by high androgen and low estrogen and progesterone receptor levels. With the dextran charcoal method, androgen binding was determined at 160 fmol/mg protein corresponding to approximately 100,000 binding sites per cell in whole cell binding assays. The estrogen and progesterone receptor contents were between 8 and 18 fmol/mg protein. The proliferation of MFM-223 cells was significantly inhibited by doses greater than 0.01 nM dihydrotestosterone. The androgenic inhibition of cell proliferation was antagonized by the antiandrogens cyproterone acetate and hydroxyflutamide. In spite of the low estrogen receptor content, MFM-223 cell proliferation was slightly enhanced by 10 nM 17 beta-estradiol. Treatment with 17 beta-estradiol or dihydrotestosterone failed to provoke an increase of the progesterone receptor level. MFM-223 cells have characteristic patterns of isoenzyme polymorphism and of karyotype alterations revealing marker chromosomes and homogeneously staining regions. In the spectrum of human mammary carcinoma cell lines, MFM-223 cells offer a unique model to investigate molecular mechanisms of androgen receptor action.
...
PMID:Androgen sensitivity of the new human breast cancer cell line MFM-223. 191 90

Surgical specimens of 62 patients with fibrocystic disease, 39 with fibroadenoma and 11 with intraductal papilloma were evaluated with ER-ICA and PgR-ICA methods. Positive nuclear staining was only observed in the epithelial components. The myoepithelium, myofibroblasts, fibroblasts and the so called apocrine epithelium, however, did not contain steroid receptors. Some steroid receptor negative cases occurred among the atrophic and non-proliferating fibrocystic diseases. In the proliferating benign alterations, particularly in those considered preneoplastic, e.g. radial scar, ductal and lobular atypical epithelioses, such as carcinoma lobulare in situ and florid intraductal papilloma there was a positive staining for estrogen receptor and progesterone receptor in the epithelial cells. Authors' results seem to serve as a theoretical basis for the hormonal influence of precarcinomatous cases and to explain the success of antisteroid therapy in patients with fibrocystic disease.
...
PMID:Immunohistochemical analysis of estrogen and progesterone receptors in benign breast diseases. 193 96

A new immunohistochemical method using a monoclonal estrogen receptor (ER) antibody and a progesterone receptor (PR) antibody has been performed to determine hormonal receptors on Bouin's liquid fixed and paraffin embedded tissue. This technique has been evaluated by comparison with conventional immunohistochemistry on frozen sections for 100 surgical biopsy specimens of breast carcinoma Erica (C) Prica (C); in 77 of these cases it was compared with enzyme immunoassay analyses (ER-EIA, PR-EIA). After a pretreatment by proteinase K for ER, the two specific monoclonal antibodies ER or PR were incubated overnight and revealed with a streptavidin biotin complex. The specific staining for ER and PR were exclusively located in the nuclei of cancer cells in both paraffin for ER and PR were exclusively located in the nuclei of cancer cells in both paraffin and frozen sections. The results on paraffin-embedded material were compared successively with ERICA (C) and ER-EIA and with PRICA (C) and PR-EIA. In 100 breast infiltrating carcinomas studied simultaneously on both paraffin and frozen sections, the concordance was 82% for ER and 85% for PR. In 77 breast carcinoma studied simultaneously on paraffin sections and EIA, the concordance was 74% for ER and 79.2% for PR. These results suggest that in the absence of frozen material, an immunohistochemical method on paraffin-embedded material can be used with a lower sensibility than on frozen sections. However, the detection of both ER and PR allows the identification of the hormondependent cases.
...
PMID:[Human breast cancer embedded in paraffin, fixed in Bouin's fluid. Immunohistochemical analysis of estrogen and progesterone receptors]. 195 56

The antiprogestin RU486 has been shown to inhibit the growth of a number of tumor cell lines and solid tumors which contain significant concentrations of progesterone receptor (PgR). It has been suggested that growth suppression may be due to a PgR-mediated cytotoxic effect. The R3327 HI prostatic carcinoma of the rat is considered to be a model for human prostatic carcinoma which has become resistant to androgen deprivation therapy. Since it is possible to induce high concentrations of PgR in this tumor with estrogen, it was of interest to investigate the possibility that RU486 could suppress its growth. Growth was assessed by tumor diameter, [3H]thymidine uptake and histopathological appearance after 2 or 8 weeks treatment with RU486 alone, diethylstilbestrol (DES) alone, and combined RU + DES treatment as compared with control animals. Tumor growth was not affected significantly by DES treatment alone. RU486 treatment alone suppressed PgR content and resulted in only insignificant inhibition of growth. However, when significant PgR concentrations were maintained by combined treatment with DES, RU486 significantly suppressed tumor growth (0.01 less than P less than 0.05 vs controls). This was accompanied by atrophy of the glandular epithelium. The results support the hypothesis that growth suppression may be brought about by a PgR-mediated mechanism. The data suggest that it may be possible to treat androgen-insensitive prostatic carcinoma by a new form of hormonal treatment.
...
PMID:Suppression of the growth of the androgen-insensitive R3327 HI rat prostatic carcinoma by combined estrogen and antiprogestin treatment. 195 8

Seventy-two patients with advanced breast carcinoma (42% bone, 25% visceral, 5.5% soft tissue, and 27.5% multiple site metastases) were evaluated to determine the relationship between tumor expression of the estrogen-regulated protein pS2, estrogen receptor (ER) or progesterone receptor (PgR) content, and response to hormonal therapy. Twenty-nine % of tumors were pS2 positive, 64% were ER positive, and 29% were PgR positive. Of the ER-positive patients (n = 43), 15 (35%) had greater than 10% of the invasive carcinoma which immunostained for pS2 (these were considered pS2 positive). Only 3 of 24 ER-negative tumors were pS2 positive. A weak association between pS2 expression and ER content (P = 0.08) but not PgR content was observed. Of pS2-positive patients, 52% had a partial or complete response to hormonal therapy. In 24% of pS2-positive patients the disease stabilized with treatment. In contrast, 27% of pS2-negative patients had a partial or complete response. In 10% of these patients the disease stabilized. Similar associations between therapeutic response and ER or PgR were not observed. The odds of having a clinical response to hormonal therapy was greater for pS2-positive than for ER- or PgR-positive tumors. pS2 expression may define a subset of ER-positive tumors that are more likely to respond to hormonal treatment.
...
PMID:pS2 expression and response to hormonal therapy in patients with advanced breast cancer. 198 78

Estrogen and progesterone receptors were studied in fine-needle aspiration biopsy specimens of 56 patients with primary, recurrent, or metastatic breast carcinoma. The ligands, 17 B-estradiol-6-carboxymethyloxine-bovine serum albumin fluorescein isothiocyanate (FITC-BSA estradiol) and hydroxyprogesterone hemisuccinate bovine serum albumin tetramethyl rhodamine isothiocyanate (TMRITC-BSA progesterone), were used in the fluorescent cytochemical method. The findings obtained from the aspirated cells with the use of the fluorescent cytochemical technique were compared with results obtained from the cell population of the same tumor after removal with the use of both the fluorescent cytochemical technique and the biochemical dextran-coated charcoal (DCC) assay. For the needle aspirates, there was 89% concordance for estrogen receptor and 86% concordance for progesterone receptor between biochemical and cytochemical results. A high degree of correlation was also demonstrated between fine-needle aspirates and imprint preparations with the use of the cytochemical technique. This study suggests that the fluorescent cytochemical technique is an effective tool in assessment of estrogen and progesterone receptor content in fine-needle aspirates of primary and metastatic breast cancer. The fluorescent cytochemical technique can be performed easily at community hospitals and is well suited for specimens of insufficient size for biochemical assay.
...
PMID:Fluorescent cytochemical detection of estrogen and progesterone receptors in breast fine-needle aspirates. 198 50

Most studies of secretory carcinoma of the breast have been single case reports or separate analyses of the problem in either children or adults. We studied 10 female patients, aged 5 to 87 years. Most patients presented with a palpable mass, often near the areola. Five of six tumors were estrogen receptor negative; three analyzed for progesterone receptor were positive. Histologic patterns present in varying proportions were "classic" secretory carcinoma with microacini, abundant secretion with papillary features, and with prominent solid and papillary apocrine features. The tumors had strong reactivity for alpha-lactalbumin, S100, and carcinoembryonic antigen (polyclonal) and were negative for gross cystic disease fluid protein and anti-carcinoembryonic antigen (monoclonal). Six patients had mastectomy; four had local excision; none had axillary nodal metastases initially. With follow-up of 3 to 72 months (mean, 47 months; median, 48 months), two patients treated by local excision had local recurrences, one patient had axillary nodal metastases. All patients are alive. Comparison of patients under and over 30 years of age revealed one important difference: younger patients had a longer interval between detection and biopsy-30 vs 2 months. Treatment recommendations are initial wide excision or quadrantectomy with low axillary dissection in most cases and, in premenarchal patients, strong effort to preserve the breast bud without jeopardizing local control.
...
PMID:Secretory carcinoma of the breast. 199 79

The results of flow cytometric analysis of ploidy and S-phase fraction for invasive breast cancers have been compared with various clinical and pathologic parameters by many investigators. Ploidy usually has been found to be associated with histologic type, tumor grade, and S-phase fraction values, but not with patient age, menopausal status, tumor size, axillary nodal status, estrogen receptor status, or progesterone receptor status. S-phase fraction values have correlated with histologic type, grade, estrogen receptor status, and progesterone receptor status, but not with menopausal status or axillary nodal status. Although in several studies ploidy and S-phase fraction have been compared with patient outcome, only a few of these reports have stratified data according to the histologic types and grades of the neoplasms. There is conflicting information regarding the value of ploidy analysis for women with either node-negative or node-positive breast carcinoma. Data from a few studies seem to indicate that S-phase fraction alone or in combination with ploidy may be more important prognostically than ploidy alone, although the results have not been uniform. More studies that examine ploidy, S-phase fraction, various important clinical and pathologic variables, and outcome for patients with invasive mammary cancer must be performed before the clinical importance of DNA analysis by flow cytometry becomes known.
...
PMID:Ploidy analysis and S-phase fraction determination by flow cytometry of invasive adenocarcinomas of the breast. 200 15

More than 60 breast cancer specimens were screened for their expression status of 25 different proto-oncogenes. The screening method is based on in vitro synthesis of a radioactive cDNA copied from the total cellular RNA of tumor tissue. This cDNA is hybridized to cloned oncogene probes which are immobilized to a GeneScreen membrane. Frequently multiple oncogenes were found expressed although expression levels were rather moderate. 25-30% of the analyzed tumors showed significant expression of either erbB, src, raf1, lck or H-ras. Although neu expression--an oncogene believed to be particular relevant as prognostic parameter for mamma carcinoma--was screened for most of the tumors with a heterologous gene probe, expression signals could be detected in about 20% cases. The only notable correlation with classical clinical parameters such as tumor size and proliferation stage, hormone receptor status and different DNA indices was the observation that tumors lacking the progesterone receptor frequently express multiple oncogenes. Advantages and limitations of the cDNA/dot-blot screening for oncogene expression are discussed.
...
PMID:Expression of oncogenes in human breast cancer specimens. 201 53


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---